pharma-software
(3)
Enjamb
Enjamb (YC P26) builds full-stack AI agents for biopharma R&D that run a drug program from discovery through FDA approval. Its agents sit on top of legacy pharma systems - Benchling, Veeva, Medidata, SAS - with no migration, doing the work across clinical evidence, trial design, statistical programming, and regulatory submissions while keeping a visible source-to-submission trail. Founded in 2025 by Rayan Mubarak and Maadhav Deekshitha, the San Francisco company raised a $650K pre-seed and says its platform was used by 500+ employees at major pharma firms within weeks of launch.
MetaCell
MetaCell is a life-science software company staffed by scientists and software engineers who turn messy neuroscience and biology data - microscopy, MRI, EEG, electrophysiology, biologically accurate simulations - into usable, shareable, enterprise-grade online tools. Founded by the trio behind the OpenWorm project, MetaCell builds custom scientific software, cloud workspaces, and data pipelines for pharma companies and top research institutions including Johnson & Johnson, Pfizer, Biogen, Eisai, the Allen Institute, the Chan Zuckerberg Initiative, and universities like Princeton, Yale, and UCL.
Mike Stapleton
Mike Stapleton is the Chief Business Officer of QbDVision, the Austin-based software company building a Digital CMC platform for pharma and biotech. He spent three decades moving between the lab bench, the boardroom, and the consulting deck - senior scientist at BP, COO at Accelrys, leader at Life Technologies, PerkinElmer, Merck, Microsoft, and Accenture - before joining QbDVision's board and then stepping in to run its commercial strategy. His argument is contrarian for a software executive: the bottleneck in drug development is not the platform, it is the people willing to standardize how an industry handles its data.